Immunic (IMUX) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Inovio Pharmaceuticals (INO) over the past year, losing 15.8% versus a loss of 57.4%. Over five years, IMUX leads with a -91.3% price change compared with -98.7% for INO. Inovio Pharmaceuticals is the larger company by market cap ($113.2 million vs $111.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | INO |
|---|---|---|
| Share price | $8.14 | $1.10 |
| Market cap | $111.00M | $113.22M |
| 1-day change | +7.61% | +0.46% |
| YTD return | +41.57% | -37.36% |
| 1-year return | -15.81% | -57.42% |
| 5-year return | -91.28% | -98.71% |
| EPS (TTM) | $-3.83 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $2.72 |
| 52-week low | $5.06 | $0.56 |
| Distance from 52-week high | -53.33% | -59.74% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +429.69% | +189.50% |
| Average volume | 284.68K | 3.86M |
| Shares outstanding | 13.64M | 103.40M |
| Employees | 100 | 112 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed INO by 41.6 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
IMUX vs INO FAQ
Which is bigger, Immunic or Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) is larger, with a market capitalization of $113.22M compared with $111.00M for Immunic (IMUX).
Which stock has performed better over the past year, IMUX or INO?
IMUX returned -15.81% over the past 12 months, compared with -57.42% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.